{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.0","upperLimit":"61.0","value":"27.3"},{"groupId":"OG001","lowerLimit":"16.7","upperLimit":"76.6","value":"45.5"},{"groupId":"OG002","lowerLimit":"2.3","upperLimit":"51.8","value":"18.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"description":"Percentage of participants with a reduction of mean GH levels to \\< 2.5 µg/L at 3 months.","dispersionType":"95% Confidence Interval","groups":[{"description":"Enrolled patients were randomized to 20mg pasireotide LAR.","id":"OG000","title":"Pasireotide LAR 20mg"},{"description":"Enrolled patients were randomized to 40mg pasireotide LAR.","id":"OG001","title":"Pasireotide LAR 40mg"},{"description":"Enrolled patients were randomized to 60mg pasireotide LAR.","id":"OG002","title":"Pasireotide LAR 60mg"}],"paramType":"NUMBER","populationDescription":"FAS: Comprises all patients to whom study treatment has been assigned by randomization. According to the intent to treat principle, patients were analyzed according to the study treatment they have been assigned to during the randomization procedure.","reportingStatus":"POSTED","timeFrame":"Month 3","title":"GH Response at Month 3 by Randomized Dose","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}